Cognition Therapeutics Inc (NASDAQ:CGTX) does about 753.13K shares in volume on a normal day but saw 2068446 shares change hands in the recent trading day. The company now has a market cap of 16.03M USD. Its current market price is $0.26, marking a decrease of -12.93% compared to the previous close of $0.30. The 52 week high reached by this stock is $2.63 whilst the lowest price level in 52 weeks is $0.28.
The consensus objective for the share price is $3.25, suggesting that the stock has a potential upside of 92.0% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on December 19, 2024 when B. Riley Securities upgraded the stock to “Buy” and issued a price target of between $1 and $1.50. Oppenheimer initiated its price target at $22.
The current price level is -26.71%, -32.35%, and -50.19% away from its SMA20, SMA50, and SMA200 respectively, with the CGTX price moving above the 50-day SMA on current market day. Cognition Therapeutics Inc (CGTX) stock is down -21.67% over the week and -40.95% over the past month. Its price is -63.14% year-to-date and -90.13% over the past year.
To reach the target analysts have set, the stock logically needs to grow 92.0 percent from here.
Outstanding shares total 61.97M with insiders holding 0.59% of the shares and institutional holders owning 18.80% of the company’s common stock. The company has a return on investment of -265.34% and return on equity of -161.93%. The beta has a value of 0.76. Price to book ratio is 1.31.
